According to the American Cancer Society (ACS), Thyroid cancer accounted for approximately 47,230 in women and 15,220 in men in the United States in the year 2015. Increase in geriatric population and rising prevalence of hyperthyroidism and hypothyroidism patients are driving the Global Thyroid Cancer treatment market. Thyroid cancer is also known as papillary carcinoma is cancer that develops from the tissues of the thyroid gland. The type of cancer in which cells grows abnormally and have the potential to spread to other parts of the body. Symptoms can include swelling or a lump in the neck. Follicular cancer, medullary cancer, and Anaplastic cancer are different types of thyroid cancers. The treatments which is available for thyroid cancer are the surgical removal of the thyroid gland, radioactive ablation, and thyroid stimulating hormone (TSH) suppression therapy. In the initial stage or metastasis, stage chemotherapy has also been opted for the treatment.
|Value (USD Million)
|Key Companies Profiled
|Baxter International Inc. (United States), Mylan Pharmaceuticals Inc. (United States), Alara Pharmaceuticals Corp. (United States), Bristol Myers Co. (United States) and Abbott Laboratories (United States)
This growth is primarily driven by Increasing prevalence and incidence of thyroid cancer, Increasing risk factors and high environmental exposure of thyroid cancer patients and Government support and reimbursement policies for thyroid cancer treatment market..
Globally, a noticeable market trend is evident The high development figure for the thyroid growth therapeutics market is credited to a strong pipeline. The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Baxter International Inc. (United States), Mylan Pharmaceuticals Inc. (United States), Alara Pharmaceuticals Corp. (United States), Bristol Myers Co. (United States) and Abbott Laboratories (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market is concentrated by few players. Once the above molecules get approved, it will Intensify the competition in Thyroid Cancer Market which will result in substantial growth in the market. The competition in the market appears to be less. Some effective treatments like Surgery exist and chemotherapy drugs are in practice. Companies such as Doxorubicin aims at managing conditions are prone to get larger success in the future.
Key Developments in the Market:
On February 2018, The National Institute for Health and Care Excellence (NICE) has issued its final appraisal decision recommending Lenvima (lenvatinib) for the treatment of differentiated thyroid carcinoma.
There are 27 molecules which are in different stages of development for thyroid cancer treatment. There are four molecules in Phase III and Pre-registration. These drugs are likely get approved in the next 7 years. Zactima, XL184 and, Zybrestat have been granted orphan drug status by the FDA.
The high development figure for the thyroid growth therapeutics market is credited to a strong pipeline.
Market Growth Drivers:
Increasing prevalence and incidence of thyroid cancer, Increasing risk factors and high environmental exposure of thyroid cancer patients and Government support and reimbursement policies for thyroid cancer treatment market.
Avoiding over-treatment and over-diagnosis in patients with the lower-risk disease while promptly identifying those patients with more advanced or at high-risk disease requiring aggressive treatment is the clinical challenge for this market.
Exposure to radiation or patient undergoing radiation therapy may hamper the market.
The increasing use of powerful diagnostic tools that leads to the discovery of an increasing number of small papillary thyroid cancer.
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Thyroid Cancer Treatment Market
- Analysis about New Entrants in Thyroid Cancer Treatment Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators
Against this Challenging Backdrop, Thyroid Cancer Treatment Study Sheds Light on
The Thyroid Cancer Treatment Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Thyroid Cancer Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Thyroid Cancer Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.